Sandra Mollé

Novartis (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index765citations35works4.72yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(26), PI3K/AKT/mTOR signaling in cancer(21), Synthesis and biological activity(10), Synthesis of Tetrazole Derivatives(6), Microtubule and mitosis dynamics(2)

Publications35 total

Author Correction: Targeting the SHOC2–RAS interaction in RAS-mutant cancers

1 cited

Nature·2025· 1 citedOpen Access

Targeting the SHOC2–RAS interaction in RAS-mutant cancers

13 cited

Nature·2025· 13 citedOpen Access

QUALITY OF CARE IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: RESULTS OF THE FIRST YEAR OF THE ‘QUALITY IN CARDIOLOGY (QIC) PROJECT’

European Heart Journal Supplements·2025

Supplementary Table 1 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 4 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure Legends from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 6 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 8 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 3 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure Legends from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Table 2 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 7 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 4 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Materials and Methods from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Data from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Data from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

Supplementary Figure 5 from Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

2023Open Access

page 1 of 2Next →

Frequent Co-authors

Daniel Guthy(31), Sauveur-Michel Maira(31), Éric Billy(30), David A. Ruddy(30), Mark Stump(30), Saskia M. Brachmann(30), Audrey Kauffmann(30), Francesco Hofmann(30), William R. Sellers(30), Barbara Herkert(29), Christian Schnell(29), Thomas Ferrat(29), Hans Voshol(29), Janina Juengert(29), Grégory Marszalek(29), Malika Kazic-Legueux(29), Mitko Ristov(29), Michael N. Hall(29), Hélène Erasimus(28), Keith Calkins(28)